Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical...

Area of Science:

• Pharmacogenomics and personalized medicine research.
• Health economics and outcomes research.
• Evidence-based healthcare policy and funding.

Background:

• Personalized medicines offer targeted treatments but face challenges in demonstrating clinical efficacy and cost-effectiveness.
• Robust and appropriate decision-making processes are crucial for funding novel medical interventions.
• Current evaluation methods may not fully capture the value of personalized medicine.

Purpose of the Study:

• To propose enhanced research methodologies for evaluating personalized medicines.
• To explore the role of managed-entry funding programs in facilitating access to innovative therapies.
• To identify and address practical and ethical considerations associated with these programs.

Main Methods:

• Advocating for the integration of diverse research designs beyond traditional randomized controlled trials.
• Examining the utility of observational studies and single-arm trials for personalized medicine evaluation.
• Analyzing the framework and implications of managed-entry funding, including coverage with evidence development.

Main Results:

• Randomized trials alone are insufficient for comprehensive personalized medicine assessment.
• Managed-entry programs can provide early access to treatments with uncertain outcomes.
• Practical and ethical challenges necessitate careful planning and resolution for successful implementation.

Conclusions:

• A hybrid approach combining randomized trials with real-world evidence is essential for personalized medicine evaluation.
• Managed-entry funding models offer a pragmatic solution for balancing innovation, access, and evidence generation.
• Addressing the complexities of managed-entry programs is critical for realizing the full potential of personalized medicine.